Evidence map›Paper›PMID 24876609›Full record

ArticleJournal of diabetes science and technology2014

Impact of a reduced error range of SMBG in insulin-treated patients in Germany.

Oliver Schnell, Michael Erbach

Open access · bronzeAbstract read
In one paragraph

Article in Journal of diabetes science and technology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy.The European journal of health economics : HEPAC : health economics in prevention and care · 2020
    Review
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Performance of Cleared Blood Glucose Monitors.Journal of diabetes science and technology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Oliver SchnellForschergruppe Diabetes eV, Helmholtz Center Munich, Munich-Neuherberg, Germany Oliver.Schnell@lrz.uni-muenchen.de.
Michael ErbachSciarc Institute, Baierbrunn, Germany.
Helmholtz Zentrum München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modeling approaches demonstrate that improvement in the accuracy of blood glucose (BG) meters may lead to cost savings. An improvement of accuracy of BG meters on the basis of a reduction in error range from 20% to 5% has been reported to be associated with substantial cost savings in Germany. The aim of this study is to analyze potential cost savings related to a reduction in error range from 20% to 15% and 10% of glucose meters in Germany. The health economic analysis included the number of type 1 diabetic and the number of insulin-treated patients in Germany, the costs for glucose monitoring, a model on the effects of the improvement of accuracy on the impact of severe hypoglycemic episodes, HbA1c, and subsequently myocardial infarctions and the costs of diabetes-related complications in Germany. In the model, a reduction of 1% and 3.5% reduction in severe hypoglycemic episodes, and a 0.14% and 0.28% reduction in HbA1c was included. In type 1 diabetes the savings could be equal to a reduction in health care expenditures of more than €1.0 million (20% vs 15% error range) and €3.4 million (20% vs 10% error range). Respectively, potential savings of more than €6.0 million and €20.1 million were calculated for the group of insulin-treated patients. The model demonstrates that a reduction of error range of BG meters from 20% to 15% and 10% may translate into substantial savings for the German health care system.

Indexed as

Health Care CostsBiomarkersBlood GlucoseBlood Glucose Self-MonitoringCost SavingsDiabetes Mellitus, Type 1Drug CostsGermanyGlycated HemoglobinHealth ExpendituresHumansHypoglycemiaHypoglycemic AgentsInsulinModels, EconomicPredictive Value of TestsBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinaccuracycost analysisdiabeteshypoglycemiaself-monitoring of blood glucose

Identifiers

PMID24876609
PMCPMC4455448
OpenAlexW2130947933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.